DK1237543T3 - Brusesammensætning indeholdende histamin H2-antagonist - Google Patents

Brusesammensætning indeholdende histamin H2-antagonist

Info

Publication number
DK1237543T3
DK1237543T3 DK00980395T DK00980395T DK1237543T3 DK 1237543 T3 DK1237543 T3 DK 1237543T3 DK 00980395 T DK00980395 T DK 00980395T DK 00980395 T DK00980395 T DK 00980395T DK 1237543 T3 DK1237543 T3 DK 1237543T3
Authority
DK
Denmark
Prior art keywords
antagonist
composition containing
containing histamine
shower composition
shower
Prior art date
Application number
DK00980395T
Other languages
Danish (da)
English (en)
Inventor
John Migton
M Mamoun Hussein
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1237543T3 publication Critical patent/DK1237543T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00980395T 1999-12-06 2000-11-16 Brusesammensætning indeholdende histamin H2-antagonist DK1237543T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/455,233 US6264984B1 (en) 1999-12-06 1999-12-06 Effervescent histamine H2 antagonist composition

Publications (1)

Publication Number Publication Date
DK1237543T3 true DK1237543T3 (da) 2006-01-16

Family

ID=23807966

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00980395T DK1237543T3 (da) 1999-12-06 2000-11-16 Brusesammensætning indeholdende histamin H2-antagonist

Country Status (18)

Country Link
US (1) US6264984B1 (ko)
EP (1) EP1237543B1 (ko)
JP (1) JP2003515553A (ko)
KR (1) KR100795259B1 (ko)
CN (1) CN1211077C (ko)
AR (1) AR030172A1 (ko)
AT (1) ATE309783T1 (ko)
AU (1) AU1766101A (ko)
BR (1) BR0015779A (ko)
CA (1) CA2394902C (ko)
CY (1) CY1105495T1 (ko)
DE (1) DE60024132T2 (ko)
DK (1) DK1237543T3 (ko)
ES (1) ES2252078T3 (ko)
MX (1) MXPA02005534A (ko)
PE (1) PE20010909A1 (ko)
WO (1) WO2001039750A1 (ko)
ZA (1) ZA200203168B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
US9717726B2 (en) * 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
WO2015157729A1 (en) * 2014-04-11 2015-10-15 Wilmink Michael Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant
CN105997922A (zh) * 2016-06-12 2016-10-12 佛山市腾瑞医药科技有限公司 一种盐酸雷尼替丁泡腾片及其制备方法
EP3558296B1 (en) 2016-12-23 2023-06-28 Maregade RX, LLC Low dose product and method for treating diarrhea

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593065B1 (fr) 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
FR2633181B1 (fr) 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
DE4027927A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Brausekomponente und verfahren zu ihrer herstellung
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
ES2126147T3 (es) 1993-09-09 1999-03-16 Gerhard Gergely Granulado efervescente y procedimiento para su preparacion.
WO1995010274A1 (en) 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
IL112779A (en) 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
ES2136157T3 (es) 1994-03-01 1999-11-16 Gerhard Gergely Producto granular o comprimido que contiene un sistema efervescente y una sustancia farmaceutica activa, asi como un procedimiento para su preparacion.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations

Also Published As

Publication number Publication date
MXPA02005534A (es) 2002-11-29
WO2001039750A1 (en) 2001-06-07
DE60024132T2 (de) 2006-08-03
DE60024132D1 (de) 2005-12-22
EP1237543B1 (en) 2005-11-16
BR0015779A (pt) 2002-07-09
AU1766101A (en) 2001-06-12
EP1237543A1 (en) 2002-09-11
US6264984B1 (en) 2001-07-24
KR20020070309A (ko) 2002-09-05
CA2394902A1 (en) 2001-06-07
CY1105495T1 (el) 2010-04-28
ZA200203168B (en) 2003-09-23
AR030172A1 (es) 2003-08-13
CN1211077C (zh) 2005-07-20
JP2003515553A (ja) 2003-05-07
CN1407885A (zh) 2003-04-02
CA2394902C (en) 2006-08-08
ATE309783T1 (de) 2005-12-15
PE20010909A1 (es) 2001-11-11
ES2252078T3 (es) 2006-05-16
KR100795259B1 (ko) 2008-01-15
EP1237543A4 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DE60023167T2 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
ZA200408335B (en) Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors.
MA28393B1 (fr) Dérivés de triazole servant d'antagonistes de la vasopressine
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
ATE259363T1 (de) Piperazinderivate als 5-ht1b antagonisten
HK1099292A1 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
DE60018989D1 (de) N-carbamoyloxyalkyl-substituierte azolium-verbindungen
DK1440059T3 (da) 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
DE69939053D1 (de) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten
ATE416173T1 (de) 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4- benzylpiperidine als nmda-rezeptor-antagonisten
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
ATE305920T1 (de) Bradykinin receptorantagoniste
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
IL144720A0 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
MA26890A1 (fr) Metabolites agonistes/ antagonistes d'oestrogenes
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
ATE277043T1 (de) Vitronectin rezeptor antagonist
DK1237543T3 (da) Brusesammensætning indeholdende histamin H2-antagonist
DE60009931D1 (de) Muscarin-antagonisten
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
EE200300335A (et) Histamiiniretseptori antagonistid
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten